MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1

BMC Urology

Volumn 13, Issue , 2013, Pages

  Olsson, Hans ^a   Hultman, Per ^a   Rosell, Johan ^b   Söderkvist, Peter ^a   Jahnson, Staffan ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Regional Cancer Centre   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONFORMATION; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD; PROGNOSIS; PYROSEQUENCING; SCREENING; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENES, P53; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84872807417     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-13-5     Document Type: Article

References (48)

1. Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. Andius P, Holmang S, BJU Int 2004 93 7 980 984 10.1111/j.1464-410X.2003.04764.x 15142147 (Pubitemid 38758618)
2. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. Shahin O, et al. J Urol 2003 169 1 96 100 discussion 100 10.1016/S0022-5347(05)64044-X 12478112 (Pubitemid 35461560)
3. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Stein JP, et al. J Clin Oncol 2001 19 3 666 675 11157016 (Pubitemid 32120143)
4. Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Bostrom PJ, et al. Expert Rev Anticancer Ther 2010 10 12 1891 1902 10.1586/era.10.183 21110756
5. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? Herr HW, Donat SM, Dalbagni G, J Urol 2007 177 1 75 79 discussion 79 10.1016/j.juro.2006.08.070 17162005 (Pubitemid 44879466)
6. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. Sjodahl G, et al. PLoS One 2011 6 4 10.1371/journal.pone.0018583
7. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND, et al. J Urol 2003 169 4 1219 1228 10.1097/01.ju.0000056085.58221.80 12629332 (Pubitemid 36323756)
8. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Pasin E, et al. Rev Urol 2008 10 1 31 43 18470273
9. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Bond GL, Levine AJ, Oncogene 2007 26 9 1317 1323 10.1038/sj.onc.1210199 17322917 (Pubitemid 46328460)
10. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Horikawa Y, et al. Oncol Rep 2008 20 1 49 55 18575717
11. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Soussi T, Wiman KG, Cancer Cell 2007 12 4 303 312 10.1016/j.ccr.2007.10.001 17936556 (Pubitemid 47539312)
12. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Knappskog S, Lonning PE, Transcription 2011 2 5 207 210 10.4161/trns.2.5.16813 22231115
13. Recent advances in p53 research and cancer treatment. Suzuki K, Matsubara H, J Biomed Biotechnol 2011 2011 10.1155/2011/978312
14. The RP-Mdm2-p53 pathway and tumorigenesis. Miliani de Marval PL, Zhang Y, Oncotarget 2011 2 3 234 238 21406728
15. p53: the attractive tumor suppressor in the cancer research field. Ozaki T, Nakagawara A, J Biomed Biotechnol 2011 2011 10.1155/2011/603925
16. The MDM2-p53 interaction. Moll UM, Petrenko O, Mol Cancer Res 2003 1 14 1001 1008 14707283 (Pubitemid 38044975)
17. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Bond GL, et al. Cell 2004 119 5 591 602 10.1016/j.cell.2004.11.022 15550242 (Pubitemid 39535748)
18. Reactivation of p53: from peptides to small molecules. Brown CJ, et al. Trends Pharmacol Sci 2011 32 1 53 62 10.1016/j.tips.2010.11.004 21145600
19. Patented inhibitors of p53-Mdm2 interaction (2006-2008). Weber L, Expert Opin Ther Pat 2010 20 2 179 191 10.1517/13543770903514129 20100001
20. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Lauria A, et al. Curr Med Chem 2010 17 28 3142 3154 10.2174/092986710792232021 20666726
21. Immunohistochemical Evaluation of Cell Cycle Regulators: Impact on Predicting Prognosis in Stage T1 Urinary Bladder Cancer. Olsson H, et al. ISRN Urology in press
22. Olsson H, et al. Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours Scand: J Urol 2012
23. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T, et al. Anticancer Res 2004 24 2B 1011 1023 15161057 (Pubitemid 38625052)
24. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Konecny GE, et al. Clin Cancer Res 2011 17 6 1591 1602 10.1158/1078-0432.CCR-10-2307 21278246
25. CREG1 enhances p16(INK4a) -induced cellular senescence. Moolmuang B, Tainsky MA, Cell Cycle 2011 10 3 518 530 10.4161/cc.10.3.14756 21263217
26. Mostofi FK, Davis CJ, Sesterhenn IA, et al. Histological typing of urinary bladder tumours Berlin, Heidelberg, New York: Springer 2 1999
27. TNM Classification of Malignant Tumours Oxford: Wiley-Blackwell, Sobin LH, Gospodarowicz MK, Wittekind C, 7 2009
28. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. Cho KS, et al. J Urol 2009 182 6 2625 2630 10.1016/j.juro.2009.08.083 19836779
29. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Algaba F, Curr Opin Urol 2006 16 5 367 371 10.1097/01.mou.0000240311.08701.55 16905984 (Pubitemid 44231714)
30. p53 predictive value for pT1-2 N0 disease at radical cystectomy. Shariat SF, et al. J Urol 2009 182 3 907 913 10.1016/j.juro.2009.05.024 19616250
31. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Hitchings AW, et al. Br J Cancer 2004 91 3 552 557 10.1038/sj.bjc.6601954 15226775 (Pubitemid 39093578)
32. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. Shariat SF, et al. J Clin Oncol 2004 22 6 1014 1024 10.1200/JCO.2004.03.118 14981102 (Pubitemid 41095033)
33. Screening for Mutations in DNA by Single-Stranded Conformation Polymorphism (SSCP) Analysis. Perry DJ, Methods Mol Med 1999 31 105 110 21340986
34. p53 mutations in urinary bladder cancer. Berggren P, et al. Br J Cancer 2001 84 11 1505 1511 10.1054/bjoc.2001.1823 11384101 (Pubitemid 32579343)
35. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Lind H, et al. Int J Cancer 2006 119 3 718 721 10.1002/ijc.21872 16496380 (Pubitemid 43955729)
36. Association of breast cancer outcome with status of p53 and MDM2 SNP309. Boersma BJ, et al. J Natl Cancer Inst 2006 98 13 911 919 10.1093/jnci/djj245 16818855 (Pubitemid 44018921)
37. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. Ohmiya N, et al. J Clin Oncol 2006 24 27 4434 4440 10.1200/JCO.2005.04.1459 16983111 (Pubitemid 46630981)
38. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Hirata H, et al. Clin Cancer Res 2007 13 14 4123 4129 10.1158/1078-0432.CCR-07-0609 17634539 (Pubitemid 47108171)
39. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Shinohara A, et al. Cancer Sci 2009 100 12 2376 2382 10.1111/j.1349-7006.2009.01331.x 19764997
40. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Yemelyanova A, et al. Mod Pathol 2011 24 9 1248 1253 10.1038/modpathol.2011.85 21552211
41. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cote RJ, et al. Cancer Res 1998 58 6 1090 1094 9515785 (Pubitemid 28183188)
42. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Benedict WF, et al. Oncogene 1999 18 5 1197 1203 10.1038/sj.onc.1202452 10022125 (Pubitemid 29085992)
43. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Kruger S, et al. Eur Urol 2005 47 4 463 467 10.1016/j.eururo.2004.12.018 15774242 (Pubitemid 40357889)
44. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. Alhopuro P, et al. J Med Genet 2005 42 9 694 698 10.1136/jmg.2005.031260 16141004 (Pubitemid 41306059)
45. MDM2 T309G polymorphism is associated with bladder cancer. Onat OE, et al. Anticancer Res 2006 26 5A 3473 3475 17094469 (Pubitemid 44701525)
46. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Willander K, et al. Eur J Haematol 2010 85 3 251 256 10.1111/j.1600-0609.2010.01470.x 20491880
47. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Lu ML, et al. Clin Cancer Res 2002 8 1 171 179 11801555
48. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Hernandez S, et al. Clin Cancer Res 2005 11 15 5444 5450 10.1158/1078-0432.CCR-05-0122 16061860 (Pubitemid 41060820)